Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

KisoJi Biotechnology

Request full access

AI-powered therapeutic antibody discovery for oncology

Montreal, CanadaFounded 2009Biotech & Life Sciences

About KisoJi Biotechnology

KisoJi Biotechnology is a privately-held Canadian company developing therapeutic antibodies for oncology, cardiometabolic disease, and immunology. Founded in 2009 by David S. Young, M.D., the company's mission is to improve outcomes in these fields through multi-specific antibodies. Young, who serves as CEO and CSO, previously founded ARIUS Research Inc., a therapeutic cancer antibody company acquired by Roche in 2008.

The company's business model revolves around its proprietary, in-house developed antibody discovery platform, which leverages artificial intelligence. This platform integrates several core technologies: KisoMouse®, a transgenic mouse platform for generating single-domain antibodies; KisoSeek™, an AI-driven tool for structural antibody screening and paratope mapping; and KisoBody™, a platform for creating multi-specific antibodies. The company claims to have created the world's largest single-domain antibody database, with over 25 million validated antibodies, which powers its AI platform. KisoJi's approach aims to visualize the complete immune response to identify antibodies with desired properties more efficiently than traditional methods.

KisoJi's lead product candidate is KJ-103, a 'naked' anti-TROP2 antibody for treating solid tumors. Unlike antibody-drug conjugates (ADCs), KJ-103 does not have a toxic payload and instead recruits the patient's own immune cells to attack cancer cells, potentially offering a safer treatment profile. In October 2024, KisoJi announced a partnership with Cancer Research UK to advance KJ-103 into a first-in-human Phase 1/2a clinical trial. To fund this clinical advancement and further develop its platform, the company raised $41 million USD in a Series B equity financing round in late 2024, led by Investissement Québec and Lumira Ventures.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
28
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Dec 2024 $30M $120M Remiges Ventures · Fonds de solidarité FTQ · Invest Quebec · Lumira Ventures ↗
SERIES AEquity / VC Jun 2018 — — Remiges Ventures · Lumira Ventures · Fonds de solidarité FTQ —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

KisoJi Biotechnology website traffic

Latest recorded traffic for KisoJi Biotechnology is 4.4K monthly website visits, up 537.7% over the last three months. KisoJi Biotechnology's team declined 66.7% over the past year.

Latest monthly visits4.4K 3-month web change+537.7% 1-year team growth-66.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

KisoJi Biotechnology in the Montreal ecosystem

Live from Dealroom

The KisoJi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Lumira Ventures
  • Accel-Rx Health Sciences Accelerator
  • Ccrm
  • Business Development Bank of Canada
  • Fonds de solidarité FTQ
  • Remiges Ventures
  • Invest Quebec
  • AdMare BioInnovations
Employees 5 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇦 Canada100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about KisoJi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See KisoJi Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.